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Purpose. We evaluated a questionnaire to aid in the recognition of CRC risk, as well as patient interest in their risk status within an
open-access endoscopy center. Methods. A questionnaire was administered to new patients presenting for colonoscopy from May
2007 to February 2008. 287 patients were enrolled. Family history was evaluated using Amsterdam 1, II, and Revised Bethesda
criteria. Recognition of risk and referral for counseling was assessed. Patients’ interest to be contacted by a genetic counselor was
also assessed. Results. 13.2 % (38/287) of patients met Revised Bethesda criteria. Of these, 18 (47.4 %) were previously told about
theirincreasedriskforCRC.Only1patientwhometRevisedBethesdacriteria(2.6%)waspreviouslyreferredforgenetics,whereas
none of the 3 patients who met Amsterdam I or II criteria were referred. 23.7 % of high-risk patients did not want to be contacted
if found to be at increased risk for cancer. Conclusion. In our open-access endoscopy system, a signiﬁcant number of high-risk
patients remain unidentiﬁed and underreferred for genetic counseling due to numerous barriers. Our ﬁndings lend support to
taking a public health approach to identifying those at risk for Lynch syndrome by implementing universal screening of all CRC
specimens.
1.Introduction
Colorectal cancer (CRC) is the second most common cause
of cancer-related death worldwide and represents a major
health issue. The cumulative risk of getting and dying from
CRC in the US is 6% and 2.5%, respectively. About 20–30%
of colorectal cancer has a familial component, and 3–5% is
due to an inherited syndrome [1].
Studies indicate the lifetime risk of developing CRC in an
individual with a ﬁrst-degree relative with CRC is increased
by 1.6-fold to 8.0-fold [2, 3]. A meta-analysis by Johns
and Houlston of 27 studies assessing familial CRC noted
a relative risk of 2.25 in an individual with a ﬁrst-degree
relative with CRC. The relative risk doubled to 4.25 with
more than one aﬀected relative. Age at diagnosis was a strong
risk factor, as well as having a young relative with a colorectal
adenoma. This study provides strong evidence that both age
at diagnosis and number of aﬀected relatives are strong risk
factors for familial CRC [2].
Survival in CRC is primarily related to the disease stage
at the time of diagnosis. Only a minority (35%) of cases,
though, are diagnosed with localized disease, and 20–25%
are diagnosed with metastatic disease [4]. Overall ﬁve-year
survival is 62% to 94% in individuals with localized disease.
Screening or secondary prevention is deﬁned as the pre-
sumptive identiﬁcation of unrecognized disease by the
application of tests. The biological basis for CRC screening is
thatthegreatmajorityofCRCarisesfrompreexistingadeno-
matous polyps. Given the slow progression of colon polyps
to cancer, screening is cost-eﬀective and eﬃcient in detecting
early colorectal cancer. Of the various screening methods
available, colonoscopy is the most sensitive with 95% sen-
sitivity for the detection of colorectal cancer.
Detection and removal of adenomatous polyps via
screening has in part decreased the incidence of CRC from
38 cases per 100,000 in 1985 to 31 cases per 100,000 in
year 2000 [4]. Similarly, CRC-related death rate per 100,000
has declined from 30.77 in 1990 to 21.57 in 2004. This is2 ISRN Gastroenterology
supported by the National Polyp Study which has shown a
76–90% decrease in CRC incidence after colonoscopic poly-
pectomycomparedwithage-matchedcontrols[5].Thelong-
term risk of CRC was reduced by endoscopic screening and
surveillance [6–8].
For the subset of CRC that is attributable to hereditary
syndromessuchashereditarynonpolyposiscolorectalcancer
(HNPCC), or Lynch syndrome, and familial adenomatous
polyposis (FAP), screening and surveillance recommenda-
tions diﬀer signiﬁcantly from those of the average risk popu-
lation. It is crucial that physicians are aware of the guidelines
and identify individuals and families at risk for hereditary
CRC. Unfortunately, inadequate recommendations from
physicians are recognized as a major barrier to CRC screen-
ing [9].
Open-access endoscopy (OAE) is a system that allows
primary care physicians to directly access endoscopic proce-
dures without a prior oﬃce visit. OAE promotes adherence
to screening colonoscopy by increasing patients’ convenience
and decreasing patients’ costs. Properly constructed, OAE
provides eﬃcient, appropriate endoscopy in a conﬁdential
and safe manner [10, 11]. A majority of gastroenterology
practices oﬀer OAE [12]. Few studies have looked at the
appropriateness of referrals or recognition of high-risk syn-
dromes in the referral population at such centers. The goal
of this study is to evaluate the recognition of high-risk syn-
dromes and subsequent referral for genetic counseling of in-
dividuals presenting to an open-access endoscopy center.
2. Methods
NewpatientsbetweenMay2007andFebruary2008whopre-
sented for colonoscopy at one of the two open-access endo-
scopy centers aﬃliatedwiththePennStateMilton S.Hershey
Medical Center were presented with a voluntary family his-
tory questionnaire. See Table 1.
Patients were referred directly from community physi-
cians, as well as from physicians within the university. The
studywasapprovedbytheHumanSubjectsProtectionOﬃce
and informed consent obtained from all patients.
Each consenting individual completed a 14-point ques-
tionnaire obtaining details regarding personal and family
history of colorectal cancer/polyps, as well as other cancers.
It also inquired about their willingness to be contacted by a
genetic counselor if they were determined to be at high risk
based on their family history. These forms were then ana-
lyzed by a genetic professional with the Penn State Hershey
Cancer Genetics Program to determine if they met criteria
to be evaluated for Lynch syndrome based on Amsterdam I,
II, and Revised Bethesda criteria and their willingness to be
contacted for consideration of genetic counseling and test-
ing. Statistical analysis included calculation of simple per-
centages of the total.
3. Results
During the study period, a total of 1912 new patients pre-
sented to the Hershey Endoscopy Center (HEC) for colono-
scopy. An additional 806 new patients presented to the
University Physician Center (UPC) Endoscopy Suite during
the same time period. 328 patients combined from both
study sites participated in the study. 41 questionnaires, how-
ever, were eliminated due to the presence of more than one
incomplete answer. A total of 287 questionnaires were used
for the ﬁnal data analysis. Of the 287 questionnaires suc-
cessfully completed, 160 were ﬁlled out by patients seen
at HEC for a participation rate of 160/1912 or 8.4%. 104
questionnaires were successfully completed by patients seen
at the UPC Endoscopy Suite for a participation rate of
104/806 or 12.9%. For 23 of the surveys, it was not certain at
which site the patient presented for colonoscopy. See Table 2
for demographics of patients included in the ﬁnal analysis.
Only 3/287 (1.0%) patients within the study population met
criteria for Lynch syndrome, based on Amsterdam I or II
criteria, whereas 38/287 (13.2%) had personal and/or family
history that met Revised Bethesda criteria such that MSI
testing on a CRC specimen would be indicated. See Table 3
for tabulated results.
Of the 38 individuals who met Amsterdam I, Amsterdam
II, or the Revised Bethesda criteria, 26 (68.4%) expressed
interest in being contacted if determined to be at increased
risk, 9 (23.7%) did not want to be contacted, and 3 (7.9%)
did not answer the question. Of the 26 patients who ex-
pressed interest in being contacted, 24 (92.3%) were notiﬁed
regarding their increased risk by a telephone call from a
genetics professional. The remaining 2 patients who wanted
to be contacted did not return our calls. Of all patients who
successfully completed the survey, regardless of their level
of risk, 145/287 (50.5%) were willing to be contacted by a
genetic counselor if they were determined to be at increased
risk for a hereditary cancer syndrome, 30.0% or 86/287 did
not want to be contacted, and 56 (19.5%) did not answer the
speciﬁc question.
Interestingly, 25/287 (8.7%) patients who completed the
survey as part of their visit to one of the open-access endo-
scopy centers met criteria for referral to a genetic counselor
to discuss genetic testing for hereditary breast and ovarian
cancer (HBOC) syndrome which is associated with muta-
tions in the BRCA1 and BRCA2 genes. Of these 25 patients,
15 (60.0%) had given permission to be contacted if they
were determined to be at increased risk for a genetic predis-
position to cancer but 3 did not return our calls. An ad-
ditional 2 patients (0.7%) had a prior diagnosis of familial
adenomatous polyposis (FAP).
The 2008 joint guidelines of the American Cancer So-
ciety, the US Multi-Society Task Force on Colorectal Cancer,
and the American College of Radiology recommend screen-
ing of patients beginning at age 40 with a family history
of one ﬁrst degree relative with adenomatous polyps or
cancer at any age [13]. Of the ﬁrst-time colonoscopy takers
in our study population which represented 136/287 or
47.4% of those completing a family history questionnaire,
46/136 (33.8%) had a ﬁrst-degree relative with polyps and
16/136 (11.8%) had a ﬁrst-degree relative with CRC which
warranted baseline screening at 40. 4.4% (6/136) had a
history of both CRC and polyps in a ﬁrst degree relative(s).
Of the 56 patients who had either a ﬁrst degree relative with
CRC and/or polyps where earlier screening was warranted,ISRN Gastroenterology 3
Table 1: Hereditary Colorectal Cancer Syndrome Survey (IRB number 23613).
Does anyone in your family have colon POLYPS?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have COLON or RECTAL cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have UTERINE cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have STOMACH cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have PANCREATIC cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have OVARIAN cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have BRAIN cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have URETER/KIDNEY cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis
Does anyone in your family have SMALL BOWEL cancer?
Relationship to you Mother or Father’s side of family Age at diagnosis4 ISRN Gastroenterology
Table 1: Continued.
Does anyone in your family have any OTHER cancers not listed (ex. Hepatoblastoma, a childhood liver cancer; cancers of the bile duct or
gallbladder, etc.)
Relationship to you Mother or Father’s side of family Age at diagnosis
Did one of the following providers refer you for your colonoscopy? If yes, circle the provider. If not, circle other.
McGarrity, Mathew, Ouyang, Riley, Pooran, Rampertab, Smith, Bethards, Schreibman, Meitz, Mukherjee, Downey, Moyer, Biswas,
Moole, Thompson, Chase
Other
What is your age?
Have you ever had a colonoscopy before (circle)Y e s N o
If yes, when
What were the ﬁndings:
Why were you referred for today’s colonoscopy?
Have you ever been told that you are at an increased risk for colon or rectal cancer?
(circle)Y e sN o
If yes, reason given to you
Do you have a personal history of these cancers: (circle):
Colon, rectum, uterine, stomach, pancreas, ovarian, brain, gallbladder, ureter/kidney, small bowel, bile duct, breast, thyroid or any other
cancers?
Age at diagnosis
Does cancer run in your family? For each individual, list type of cancer, and estimated age when the cancer was found
If person has multiple cancers, please list them all.
Type of cancer Age at diagnosis
Mother
Father
Siblings
Grandmother (father’s side)
Grandmother (mother’s side)
Grandfather (father’s side)
Grandfather (mother’s side)
Aunts (indicate mother or father’s side)
Uncles (indicate mother or father’s side)
Nieces or Nephews
Cousins (indicate mother or father’s side)
Your children
Have you been told by your doctor that you may be at increased risk of a hereditary cancer
syndrome? (circle)Y e sN o
If so, have you been referred to a genetics counselor by your doctor? (circle)Y e sN o
If it is determined that your family may be at increased risk for a genetic predisposition to
cancer
do you want to be contacted by Dr. Maria Baker, a genetics counselor with the Penn State
Cancer Genetics Program? (circle)Y e sN o
All information will be kept conﬁdential and not released without your signed permission.ISRN Gastroenterology 5
Table 2: Patient Demographics (N = 287).
Variable N % Mean
Gender
Male 93 32.4
Female 170 59.2
Not speciﬁed 24 8.4
Age in years 54.4
<40 36 12.5
40–49 43 15.0
50–59 108 37.6
≥60 90 31.4
Not speciﬁed 10 3.5
Referral indication
Family history 62 21.6
Routine screening 56 19.5
Personal history CRC/polyps 47 16.4
Bleeding/anemia 27 9.4
Abdominal pain/hemorrhoids/stool changes 20 7.0
Inﬂammatory bowel disease 14 4.9
Other 11 3.8
Not speciﬁed 50 17.4
44 (78.6%) were above the age of 40 at the time of their ﬁrst
colonoscopy.
4. Discussion
Colorectal cancer typically occurs in individuals older than
50 owing to age-related associated risk and environmental
and/or lifestyle-related exposures [14]. Studies have shown
that 20–30% of CRC has a potentially identiﬁable genetic
cause [2]. Speciﬁc genes have been identiﬁed as the causative
factors for high-risk syndromic CRC. Amongst the high-risk
syndromes, the most common are Lynch syndrome and FAP,
which are caused by germ line mutations in the associated
g e n e sa n da c c o u n tf o r3 – 5 %o fa l lC R C[ 14–16]. Genetic
testing can reveal mutations in high-risk individuals and
their family members and help guide further screening rec-
ommendations. To adequately detect the subset of patients
with Lynch syndrome, genetic testing should be considered
in approximately 10–15% of all patients with CRC [17, 18].
Additionally, sporadic colon cancer often displays clus-
tering in families as well, though not necessarily meeting
criteria for well-deﬁned genetic syndromes. These sporadic
cases are thought to arise due to low-penetrance genes with
a number of candidate genes and polymorphisms already
identiﬁed [14, 19–21]. Current National Comprehensive
Cancer Network (NCCN) guidelines to screen such individ-
uals with familial clustering who do not meet speciﬁc criteria
include (1) to begin screening at age of 40 years or 10 years
prior to diagnosis and subsequently every 3–5 years if one
ﬁrst-degree relative <50yrs is aﬀected. (2) Screening at 40
andrepeatevery3–5yearsif2ormoreﬁrst-degreerelativesat
any age or one younger than 50 are aﬀected [13, 22]. The age
limit of 50 has further been liberalized to 60 to be considered
intheincreasedriskcategoryforCRCbythejointguidelines.
They recommend beginning screening at 40 and then every 5
yearsif1ﬁrst-degreerelativeyoungerthan60ortworelatives
over the age of 60 is aﬀected with CRC.
Our study showed that a signiﬁcant number of newcom-
ers to colonoscopy (41.2%) met criteria to warrant earlier
screening starting at 40 due to the presence of at least
one ﬁrst-degree relative with CRC or polyps according to
the joint guidelines. By this measure, 44/56 (78.6%) were
screened late. We acknowledge, though, that these guidelines
were released in early 2008.
A study of 535 CRC patients indicated that selectively
testing CRC patients with high-risk features, including age
less than 50, presence of multiple primary cancers, aﬀect-
ed ﬁrst-degree relatives with CRC or endometrial cancer, sig-
niﬁcantly improved eﬃciency. These form part of the Be-
thesda guidelines put forth by the National Cancer Institute
Workshop on HNPCC in 1997 [23, 24].
All of the above criteria, though, rely on a thorough per-
sonal and family history to aid in the recognition of high
risk syndromes and the appropriate referral of patients for
genetic counseling. Our study shows that only 18 of the 38
patients whose family history met the Revised Bethesda cri-
teria (47.4%) were recognized appropriately as high risk by
the referring physicians, indicating either inadequate history
uptake or lack of suﬃcient knowledge regarding the clinical
criteria.
A newer entity known as MYH-associated polyposis
(MAP), which is due to germline mutations in the MYH
gene, usually presents in the 4th and 5th decade and follows
an autosomal recessive mode of inheritance. Aﬀected indi-
viduals tend to have fewer polyps (less than 100) than the
classic form of FAP and are at risk for developing CRC,
as well as duodenal cancer, similar to those with FAP. Our
family history questionnaire did not ask the cumulative nu-
mber of polyps identiﬁed in patients and their relatives due
to this information typically not being known. As a result,
it was diﬃcult to distinguish concern for Lynch syndrome
versus one of the polyposis syndromes, such as FAP or MAP,
if there was only a history of CRC/polyps in the absence of
Lynch-associated cancers.
Although not one of the goals of our study, the question-
naire also helped identify families that may be at increased
risk to harbor a BRCA mutation. The criteria that were used
to determine if a family was appropriate to consider BRCA
counseling and testing are as follows: (1) 2 or more wo-
men on the same side of the family with breast cancer <50,
(2) any woman in the family with both breast and ovar-
ian cancer, (3) 2 primary breast cancers in the same woman,
(4) any woman with Ashkenazi Jewish ancestry and a history
of breast or ovarian cancer, (5) any male with breast cancer,
(6) a woman with breast cancer in her 20s or 30s regard-
less of any additional family history, and (7) at least 3 wo-
men on the same side of the family with breast cancer re-
gardless of age at diagnosis. A total of 8.7% (25/287) of the
study population met criteria which raised concern for a he-
reditary predisposition to breast and ovarian cancer but
only 1/25 or 4% had previously been referred for genetic6 ISRN Gastroenterology
Table 3: Identiﬁcation of patients with hereditary/familial risk factors (N = 287, n = 136).
Risk criterion met N % n % Late to 1st c-scope %
Hereditary risk criterion met by patient
Amsterdam I criteria 1 0.3
Amsterdam II criteria 3 1.0
Revised Bethesda guidelines 38 13.2
Familial risk criterion met by patient
Px hx of colorectal polyps 39 13.6
Px hx of colorectal cancer 6 2.1
Fx hx of colorectal polyps 100 34.8
Fx hx of colorectal cancer 94 32.8
Fx hx of CR polyps in 1st degree relative(s) 93 32.4
Fx hx of CR cancer in 1st degree relative(s) 49 17.1
Familial risk criterion met by newcomer to colonoscopy
Fx hx of CR polyps in 1st degree relative(s) 46 33.8 38 82.6
Fx hx of CR cancer in 1st degree relative(s) 16 11.8 11 68.8
Fx hx of either CR polyps and/or CRC in 1st degree relative(s) 56 41.2 44 78.6
Px hx: personal history, Fx hx: family history.
counseling. Similar to those patients at increased risk for
Lynch syndrome, as identiﬁed by meeting the Revised Be-
thesda criteria, a substantial portion of patients were un-
aware of their potential increased risk for hereditary breast
and ovarian cancer syndrome at the time of presentation for
colonoscopy.
Increasingly, open-access endoscopy (OAE) is viewed as
a way to increase access, improve convenience, and decrease
costs of CRC screening. The challenge to OAE is to pro-
vide safe and appropriate screening. A checklist format en-
compassing established guidelines for average and high-risk
individuals is critical for OAE quality control.
Implementing the family history form uncovered several
interesting points, in addition to the limited recognition of
familial cancer within the medical community. Further, it
broughttolighttheunderutilizationofgeneticcounseling,as
well as individual attitudes towards such referrals. Only 2.6%
of the study population that met criteria concerning Lynch
syndrome were referred for genetic counseling, and, inter-
estingly, 29.8% of the high-risk patients elected not to be
contacted if determined to be at increased risk.
Approximately, 10–15% of all patients with CRC should
be considered for genetic testing to identify most cases of
Lynch syndrome. A study by Grover et al. noted that 19%
(75/387)ofpatientsenrolledinthestudymetcriteriaforMSI
testing but only 17% (17/75) of the individuals meeting cri-
teria were tested [18]. Our results likewise show that a signi-
ﬁcantly small number of patients undergo genetic counsel-
ing/testing compared to the actual number of patients who
met referral criteria. Possible barriers include identiﬁcation
and referral of appropriate patients by physicians, physician
knowledge regarding familial syndromes, and the various so-
cietal guidelines, as well as patient access to genetic services.
In addition, patients may have limited knowledge regarding
the potential beneﬁts of one’s genetic information, and they
mayfearthepotentialriskofgeneticdiscriminationandhave
concerns regarding psychological and emotional adjustment
to one’s genetic test results [25–27].
One of the major limitations of the study was that a
signiﬁcant number of patients elected not to complete the
questionnaire and, of those that did, a fair number failed
to answer the questions completely. Some of the possible
reasons could be the length of the questionnaire, as well as
the use of open-ended questions, both of which increase the
amount of time required to complete the survey. Simplifying
the family history form should help to obtain a higher yield
as demonstrated by Kastrinos et al. in their open access
endoscopy study [28]. Using recursive partitioning analysis,
they developed a simple CRC risk assessment tool consisting
of 3 questions that were most informative for identifying
high-risk patients. The 3 questions consisted of (i) “Do you
have a ﬁrst degree relative with CRC or Lynch syndrome-
related cancer diagnosed before age 50?” (ii) “Have you had
CRC or polyps diagnosed before age 50?” (iii) “Do you
have ≥3 relatives with CRC?” When asked successively, these
questions identiﬁed 77% of high-risk patients and 95% of
known mutation carriers [28]. Similarily, Nathanson et al.
developed a 3-question risk assessment tool which helped to
betteridentifypatientsatincreasedriskforCRCasevidenced
by 24% of average risk patients having adenomatous polyps
in comparison to the 41% of high-risk patients [29]. The
3 questions consisted of (i) “Do you have a history of
colonic polyps or CRC?” (ii) “Do you have a family history
of CRC?” (iii) “Have you or has anyone in your family
had cancer of the uterus, ovary, stomach, intestines, or
kidneys?” Although our study demonstrated that use of a
family history questionnaire can increase the identiﬁcation
of high-risk patients, we did not have approval from the
Human Subjects Protection Oﬃce to access the results of the
colonoscopy and any biopsies taken to determine whether
they had a higher percentage of CR polyps/cancer detected
than those at average risk. As shown by our study andISRN Gastroenterology 7
others [28, 29], family history forms can signiﬁcantly in-
crease the detection of high-risk patients. Kastrinos et al.
concluded that approximately 1 in 5 patients undergoing
colonoscopy would beneﬁt from further risk assessment.
Additionally, depending on the questions utilized in the
risk assessment tool, concern for other cancer predisposition
syndromes, such as Hereditary Breast and Ovarian Cancer
syndrome can be raised as well.
Finally, an ample number of studies have investigated
physician knowledge of familial CRC syndromes, screening
and practice patterns [30–33]. They unanimously note
suboptimal knowledge of CRC screening guidelines and
criteria for familial syndromes. Interestingly, even within
the subspecialty of gastroenterology, though the majority of
gastroenterologists do obtain a family history, only a frac-
tion has typically recommended genetic counseling and ap-
propriate screening. Physician knowledge can thus prove to
be a signiﬁcant barrier to maximizing the beneﬁts of genetic
counseling and testing. Moreover, the lack of ample time
in the all-too-familiar busy clinic schedule may, in part,
attribute to inadequacies in history taking. Therein lies one
of the challenges of an open-access endoscopy center where
patients present for predetermined procedures without prior
examination by the physicians performing those procedures.
These study ﬁndings support the necessity of identifying
alternative strategies to gathering adequate family history in
a system pressed for time so as to identify high-risk famil-
ies. Given the various barriers which persist, though, all of
which prevent high-risk patients from accessing genetic ser-
vices, including both counseling and testing, a public health
approach to screening all CRC cases for Lynch syndrome
has been advocated by EGAPP, the Evaluation of Genomic
Applications in Practice and Prevention Working Group
[34]. These two approaches, utilization of a simpliﬁed clini-
cal question set and universal screening of all CRC cases for
Lynch syndrome, should be viewed as complementary to one
another, thus permitting the greatest detection of patients
and families with both familial and hereditary colorectal
cancer.
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